Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.
Standard
Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. / Kiehl, Michael G; Kraut, Ludwig; Schwerdtfeger, Rainer; Hertenstein, Bernd; Remberger, Mats; Kröger, Nicolaus; Stelljes, Mathias; Bornhaeuser, Martin; Martin, Hans; Scheid, Christoph; Ganser, Arnold; Zander, Axel R; Kienast, Joachim; Ehninger, Gerhard; Hoelzer, Dieter; Diehl, Volker; Fauser, Axel A; Ringden, Olle.
In: J CLIN ONCOL, Vol. 22, No. 14, 14, 2004, p. 2816-2825.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.
AU - Kiehl, Michael G
AU - Kraut, Ludwig
AU - Schwerdtfeger, Rainer
AU - Hertenstein, Bernd
AU - Remberger, Mats
AU - Kröger, Nicolaus
AU - Stelljes, Mathias
AU - Bornhaeuser, Martin
AU - Martin, Hans
AU - Scheid, Christoph
AU - Ganser, Arnold
AU - Zander, Axel R
AU - Kienast, Joachim
AU - Ehninger, Gerhard
AU - Hoelzer, Dieter
AU - Diehl, Volker
AU - Fauser, Axel A
AU - Ringden, Olle
PY - 2004
Y1 - 2004
N2 - PURPOSE: The role of unrelated allogeneic stem-cell transplantation in acute lymphoblastic leukemia (ALL) patients is still not clear, and only limited data are available from the literature. We analyzed factors affecting clinical outcome of ALL patients receiving a related or unrelated stem-cell graft from matched donors. PATIENTS AND METHODS: The total study population was 264 adult patients receiving a myeloablative allogeneic stem-cell transplant for ALL at nine bone marrow transplantation centers between 1990 and 2002. Of these, 221 patients receiving a matched related or unrelated graft were analyzed. One hundred forty-eight patients received transplantation in complete remission; 62 patients were in relapse; and 11 patients were refractory to chemotherapy before transplant. Fifty percent of patients received bone marrow, and 50% received peripheral blood stem cell from a human leukocyte antigen-identical related (n = 103), or matched unrelated (n = 118) donor. RESULTS: Disease-free survival (DFS) at 5 years was 28%, with 76 patients (34%) still alive (2.2 to 103 months post-transplantation), and 145 deceased (65 relapses, transplant-related mortality, 45%). We observed an advantage regarding DFS in favor of patients receiving transplantation during their first complete remission (CR) in comparison with patients receiving transplantation in or after second CR (P =.014) or who relapsed (P
AB - PURPOSE: The role of unrelated allogeneic stem-cell transplantation in acute lymphoblastic leukemia (ALL) patients is still not clear, and only limited data are available from the literature. We analyzed factors affecting clinical outcome of ALL patients receiving a related or unrelated stem-cell graft from matched donors. PATIENTS AND METHODS: The total study population was 264 adult patients receiving a myeloablative allogeneic stem-cell transplant for ALL at nine bone marrow transplantation centers between 1990 and 2002. Of these, 221 patients receiving a matched related or unrelated graft were analyzed. One hundred forty-eight patients received transplantation in complete remission; 62 patients were in relapse; and 11 patients were refractory to chemotherapy before transplant. Fifty percent of patients received bone marrow, and 50% received peripheral blood stem cell from a human leukocyte antigen-identical related (n = 103), or matched unrelated (n = 118) donor. RESULTS: Disease-free survival (DFS) at 5 years was 28%, with 76 patients (34%) still alive (2.2 to 103 months post-transplantation), and 145 deceased (65 relapses, transplant-related mortality, 45%). We observed an advantage regarding DFS in favor of patients receiving transplantation during their first complete remission (CR) in comparison with patients receiving transplantation in or after second CR (P =.014) or who relapsed (P
M3 - SCORING: Zeitschriftenaufsatz
VL - 22
SP - 2816
EP - 2825
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 14
M1 - 14
ER -
